Venus Remedies has received its first patent for a novel antibiotic combination of carbapenem and aminoglycoside. Pioneering into antibacterial portfolio, Venus has added another international patent from CIPRO (Companies and Intellectual Property Registration Office) South Africa for the antibiotic combination rationally designed to result in a pharmaceutical low dose. Overall, Venus has 80 patents for its innovative research products across the globe.
Venus Medicine Research Centre (VMRC) is working on innovating new technologies and drugs for eradicating the most fatal diseases in the world. Commenting on this achievement, Dr Mufti Suhail Sayeed, Vice President – VMRC, Venus Remedies said, “We have made progress to treat serious fatal mixed multi-bacterial infectious diseases through our novel antibiotic combination of Carbapenem and Aminoglycoside. Having received this patent grant from CIPRO, South Africa, we are hopeful of capturing a major share in the market which is upheaval with antibiotics for wide indications.”
Dr Sayeed further added, “With probable prolonged administration of most of the existing therapies, this proposed single unit injection will be a blessing for the medical fraternity as it is extremely effective even at very low concentrations. This will significantly overcome the drug resistance problem and will also reduce the side effects.”
Novel antibiotic combination is suitable for the treatment of bacterial/ multi-bacterial infections, and is particularly suitable for catering to the needs of all age groups ranging from the neonates, children, immuno compromised patients, and the ones prone to serious fatal mixed multi-bacterial infectious diseases.
In case of neonates and children, where higher doses may precipitate serious toxicities and lower doses of existing therapies do not work, dose reduction to a therapeutically effective level with reduced side effects was the greatest accomplishment with the novel antibiotic combination.
EP News Bureau — Mumbai
- Advertisement -
